JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
This certification will open new markets for the Kwality Pharma
atulya keratin & wheat protein shampoo has force of natural ingredients like extract of wheat, fenugreek, reetha & almond oil
Increases speed to market for drug developers working on nucleic acid therapeutics
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
ICMR will continue to track trends in HMPV circulation throughout the year
Subscribe To Our Newsletter & Stay Updated